← Association for Accessible Medicines
USTRNonrulemakingUSTR-2017-0010

Public Comments Regarding the Administration’s reviews and report to the President on trade agreement violations and abuses.

RIN
—
Last modified
Aug 6, 2017
Comment window
closed 3284d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Aug 6, 2017 and Aug 6, 2017. 63 other organizations filed here. The comment window closed 3284d ago.

What Association for Accessible Medicines filed (1)

Aug 6, 2017· Association for Accessible Medicines (AAM)· USTR-2017-0010-0049

We are pleased to provide input on the above-referenced matter on behalf of the Association for Accessible Medicines (AAM, formerly the Generic Pharmaceutical Association). AAM represents the manufacturers and distributors of finished generic and biosimilar medicines, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic and biosimilar industries in the United States. AAM and its members are driven by the belief that access to safe, effective and affordable generic and biosimilar medicines can improve people's lives and provide significant savings to the U.S. health care system. In 2016, AAM members manufactured over 61 billion doses of prescription medicines in the U.S. in 149 facilities located in 16 states.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (63)

See everyone who commented →
Public Comments Regarding the Administration’s reviews and report to the President on trade agreement violations and abuses. (USTR) — Association for Accessible Medicines | OpenPolis